ClinicalTrials.gg
CompletedNCT02265731Updated Aug 2, 2021

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

A Phase 1/2 interventional study of azacitadine and venetoclax in Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL), sponsored by AbbVie. Completed at 14 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-08-02.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, 1 of them phase 3. venetoclax · Lymphoma, Non-Hodgkin.

Enrollment
10th of 23
38 · median 25
Started
2014
with 2 others
Phase 1/2
5 of 23
1 open now
Registered
8th of 23
by date
Lead sponsor
10 of 23
AbbVie

Among the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, this one is the 10th largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 1/2, and was the 8th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.

03

Conditions studied

  • Non-Hodgkin Lymphoma (NHL)
  • Multiple Myeloma (MM)
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Acute Myeloid Leukemia (AML)

Keywords

  • relapsed multiple myeloma
  • refractory multiple myeloma
  • Lymphoma, Non-Hodgkin
  • Lymphoproliferative Disorders
  • Lymphatic Diseases
  • relapsed chronic lymphocytic leukemia
  • small lymphocytic lymphoma
  • relapsed small lymphocytic lymphoma
  • refractory small lymphocytic lymphoma
  • refractory chronic lymphocytic leukemia
  • acute myeloid leukemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have documented diagnosis of NHL (and exhausted options considered standard of care) as defined in the World Health Organization classification scheme and following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens. Participants with other lymphoproliferative diseases can be considered in consultation with the AbbVie medical monitor
  • Relapsed or refractory multiple myeloma participants must have been previously treated with at least one and have
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma participants must have relapsed or be refractory to standard treatments such as fludarabine based regimens or alkylator based regimens
  • Untreated AML subjects or Relapsed or refractory AML subjects must have been previously treated with at least one prior line of therapy
  • (ECOG) performance score less than or equal to 1; adequate bone marrow independent of growth factor support per local laboratory reference range; and adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening
  • Participants with a history of autologous or allogenic stem cell transplantation must have adequate blood counts independent of growth factor support and have recovered from any transplant-related toxicity(s) and be at least 100 days post- transplant (multiple myeloma) or 6 month post-autologous transplant (NHL) prior to first dose of study drug or at least 6 months post-allogenic transplant (multiple myeloma) prior to first dose of study drug and not have active (GVHD), i.e., requiring treatment

Exclusion criteria

Exclusion Criteria:

  • NHL participants who have undergone an stem cell transplant or were diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia
  • Participant tested positive for
  • Participant has a cardiovascular disability status of Class greater or equal to 2
  • Participant has a significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study.
  • Participant received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Arm A (Phase 1)

    Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)

    Drug: venetoclax

  • Experimental
    Arm B (Phase 1)

    Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

    Drug: venetoclax

  • Experimental
    Arm C (Phase 1)

    Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML)

    Drug: azacitadine · Drug: venetoclax

  • Experimental
    Arm D (Phase 2)

    Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL

    Drug: venetoclax · Drug: rituximab / IDEC-C2B8

Interventions

  • 75 mg/m2 by IV infusion or subcutaneous dosing

  • Step-up doses of venetoclax to the designated cohort dose

  • Drugrituximab / IDEC-C2B8

    Drug page: Rituximab

    375 mg/m2 on Week 6

  • Drugrituximab / IDEC-C2B8

    Drug page: Rituximab

    500 mg/m2 Week 10 Day 1 and thereafter

06

What researchers measure

Primary outcomes

  1. Number of participants having treatment-emergent adverse events

    Collect all adverse events at each visit

    Time frame: Approximately 2 years

  2. Time to maximum plasma concentration (Tmax) of venetoclax

    Time frame: Approximately 8 days

  3. Maximum plasma concentration (Cmax) of venetoclax

    Time frame: Approximately 8 days

  4. Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax

    Time frame: Approximately 8 days

  5. Objective Response Rate (Phase 2)

    The proportion of participants with response (e.g., partial, complete response) using IWCLL (International Workshop on Chronic Lymphocytic Leukemia) criteria for CLL participants will be computed for all participants with active disease at baseline (in the opinion of the investigator).

    Time frame: Approximately 48 months

Secondary outcomes

  1. Objective Response Rate (Phase 1)

    The proportion of participants with response (e.g., partial, complete response) using IWG (International Working Group) response criteria for NHL participants, IMWG (International Myeloma Working Group) response criteria for multiple myeloma participants, IWCLL (International Workshop on Chronic Lymphocytic Leukemia) criteria for CLL participants or IWG (International Working Group) criteria for AML participants will be computed for all participants with active disease at baseline (in the opinion of the investigator).

    Time frame: Approximately 48 months

  2. Minimal Residual Disease (MRD)

    Time frame: Approximately 2 years

  3. Duration of Response

    Duration of response is defined as the number of days from the participant's initial response (e.g., partial, complete response per disease-appropriate response criteria) to the day that disease progression is objectively documented.

    Time frame: Approximately 48 months

  4. Time to disease progression

    Time to disease progression is defined as the number of days from the date the subject started the study drug to the date of the subject's progression (all events of progression will be included).

    Time frame: Approximately 48 months

  5. complete response or remission (CR) rate

    CR rate will be defined as the proportion of participants who achieved a complete response or remission (CR) or complete response with incomplete bone marrow recovery or complete remission with incomplete count recovery (CRi) per the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria.

    Time frame: Approximately 48 months

  6. Partial response or remission (PR) rate

    PR rate will be defined as the proportion of subjects who achieved a nodular PR (nPR) or PR per the 2008 IWCLL criteria.

    Time frame: Approximately 48 months

  7. Progression Free Survival (PFS)

    Duration of progression-free survival (PFS) will be defined as the number of days from the date of first dose to the date of earliest disease progression or death.

    Time frame: Approximately 48 months

07

Study locations

14 sites
  • Nagoya City University Hospital /ID# 129278
    Nagoya shi, Aichi 4678602, Japan
  • NHO Nagoya Medical Center /ID# 129222
    Nagoya-shi, Aichi 460-0001, Japan
  • Aichi Cancer Center Hospital /ID# 129061
    Nagoya-shi, Aichi 464-8681, Japan
  • University of Fukui Hospital /ID# 165801
    Yoshida-gun, Fukui 910-1193, Japan
  • National Hospital Organization Kyushu Cancer Center /ID# 149741
    Fukuoka-shi, Fukuoka 811-1395, Japan
  • Kyushu University Hospital /ID# 163202
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Kobe City Medical Center General Hospital /ID# 170919
    Kobe-shi, Hyogo 650-0047, Japan
  • Tohoku University Hospital /ID# 129275
    Sendai-shi, Miyagi 9808574, Japan
  • Kindai University Hospital /ID# 169554
    Osakasayama-shi, Osaka 589-8511, Japan
  • Osaka University Hospital /ID# 169862
    Suita-shi, Osaka 565-0871, Japan
  • National Cancer Center Hospital /ID# 129044
    Chuo-ku, Tokyo 104-0045, Japan
  • The Cancer Institute Hospital Of JFCR /ID# 129277
    Koto-ku, Tokyo 135-8550, Japan
  • Toranomon Hospital /ID# 148229
    Minato-ku, Tokyo 105-8470, Japan
  • NTT Medical Center Tokyo /ID# 166281
    Shinagawa-ku, Tokyo 141-8625, Japan
08

References and documents

Publications

  • Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Humphrey K, Kim SY, Okubo S, Ogawa N, Nishimura Y, Salem AH, Maruyama D. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol. 2021 Mar;113(3):370-380. doi: 10.1007/s12185-020-03024-3. Epub 2020 Oct 23. PubMed 33094474 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Mar 2021, 77 months.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 77 months is above that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2014
First posted
Oct 16, 2014
StartActual
Sep 22, 2014
Primary completionActual
Mar 12, 2021
CompletionActual
Mar 12, 2021
Last update
Aug 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02265731
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 16, 2014
Start date
Sep 22, 2014
Primary completion
Mar 12, 2021
Completion
Mar 12, 2021
Last update
Aug 2, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion